Frequently Asked Questions
The market is segmented based on Asia-Pacific Patient Derived Xenograft (PDX) Models Market, By Type (Mice Models, Rat Models), Tumor Type (Respiratory Tumor Models, Urological Tumor Models, Lung Tumor Models, Gastrointestinal Tumor Models, Hematological Tumor Models, Gynecological Tumor Models, Others), Application (Preclinical Drug Development and Oncology Research, Precision Medicine, Co-Clinical Trials, Basic Cancer Research, Biomarker Analysis), Technique (Heterotopic Implantation, Orthotropic Implantation), End User (Contract Research Organization, Academic and Research Institutions, Pharmaceutical and Biotechnology Companies and Others) – Industry Trends and Forecast to 2030.
.
The Asia Pacific Pdx Models Market size was valued at USD 36424.39 USD Million in 2022.
The Asia Pacific Pdx Models Market is projected to grow at a CAGR of 18.4% during the forecast period of 2023 to 2030.
The major players operating in the market include Crown Bioscience , THE JACKSON LABORATORY, Champions Oncology , Charles River Laboratories, Wuxi AppTec, Oncodesign, Aragen Bioscience, Biocytogen, Bioduro, Creative Animodel, Covance , EPO Berlin-Buch GmbH, EUROPDX, Explora BioLabs, Hera BioLabs, Horizon discovery , Pharmatest Services, Urospehere SAS, Xentech, Xenopat
.
The market report covers data from the China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).
